Mesalamine - Therapeutic use
Research News and Information

Sunday, November 22, 2009

Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis.

29 Sep 2009 BACKGROUND: 5-Aminosalicylate (5-ASA) agents are the mainstay of oral therapy for ulcerative colitis (UC). Balsalazide, a prodrug of 5-ASA, has recently been approved for the treatment of UC. OBJECTIVE: To summarize current data on balsalazide and ... Read more...

Crohn's disease and secondary amyloidosis: early complication? A case report and review of the literature.

30 Aug 2009 Secondary amyloidosis is a rare but serious complication of inflammatory bowel disease (IBD), generally seen in Crohn's disease. At least 1% of patients with Crohn's disease develop amyloidosis. In the literature, the time lapse between the onset of ... Read more...

The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study.

29 Jun 2009 BACKGROUND: During intestinal inflammation white blood cells are recruited from the blood, and they represent the major contributors to tissue perpetuation of inflammation via their production of chemokines and proinflammatory cytokines. OBJECTIVES: ... Read more...

Latest indexed articles for 'Mesalamine - Therapeutic use'

These are the very latest articles for this heading:

• Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. 29 Sep 2009
• Crohn's disease, hepatosplenic T-cell lymphoma and no biological therapy: are we barking up the wrong tree? 30 Aug 2009
• Case of linear IgA bullous dermatosis-involved ulcerative colitis. 30 Aug 2009
• Crohn's disease and secondary amyloidosis: early complication? A case report and review of the literature. 30 Aug 2009
• Mesenteric ischemia is a cause of resistance to treatment in IBD. 30 Jul 2009
• The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study. 29 Jun 2009
• [The problems of compliance and adherence, using the example of chronic inflammatory bowel disease] 21 Jun 2009
• Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. 31 May 2009
• Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. 30 May 2009
• Encapsulated mesalamine granules (Apriso) for ulcerative colitis. 16 May 2009
• Comparison of the analgesic effect of ibuprofen with mesalamine after discectomy surgery in patients with lumbar disc herniation: a double-blind randomized controlled trial. 29 Apr 2009
• Incidence and short-term implications of prepouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. 29 Apr 2009
• Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. 29 Apr 2009
• Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun? 19 Apr 2009
• Therapeutic effects of Clostridium butyricum on experimental colitis induced by oxazolone in rats. 19 Apr 2009
• Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. 14 Apr 2009
• Reproductive issues in inflammatory bowel disease. 30 Mar 2009
• Hypereosinophilia due to mesalazine treatment. 30 Mar 2009
• Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease. 26 Mar 2009
• Mesalazine-induced aplastic anemia. Mar 2009

See a longer list of these articles.

Technical information about 'Mesalamine'

Definition: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)

Registry Number: 89-57-6

Descriptor UI: D019804

Alternative terms: Mesalamine; meta-Aminosalicylic Acid; meta Aminosalicylic Acid; m-Aminosalicylic Acid; m Aminosalicylic Acid; 5-Aminosalicylic Acid; 5 Aminosalicylic Acid; Mesalazine; Asacolon; Celltech Brand of Mesalamine; Ascolitin; Sanofi Synthelabo Brand of Mesalamine; Henning Berlin Brand of Mesalamine; Canasa; Salofalk; Provalis Brand of Mesalamine; Falk Brand of Mesalamine; Farmasa Brand of Mesalamine; Axcan Brand of Mesalamine; Antigen Brand of Mesalamine; Claversal; SmithKline Brand of Mesalamine; Merckle Brand of Mesalamine; Fivasa; Norgine Brand of Mesalamine; Lixacol; Schering-Plough Brand of Mesalamine; Schering Plough Brand of Mesalamine; Mesalamine Hydrochloride; Hydrochloride, Mesalamine; Mesalamine Monosodium Salt; Monosodium Salt, Mesalamine; Mesasal; GlaxoSmithKline Brand of Mesalamine; Novo-5 ASA; Novo 5 ASA; Novo5 ASA; Novopharm Brand of Mesalamine; Pentasa; Ferring Brand of Mesalamine; Yamanouchi Brand of Mesalamine; Allphar Brand of Mesalamine; Rowasa; Solvay Brand of Mesalamine; 5-Aminosalicylate; 5 Aminosalicylate; Asacol; Procter & Gamble Brand of Mesalamine; Byk Brand of Mesalamine;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Anti-Inflammatory Agents, Non-Steroidal;

Tree Number: D02.241.223.100.380.800.050.540; D02.241.511.390.700.050.500; D02.755.410.700.050.500;

History Note: 98; use MESALAMINE (NM) 1981-97